tiprankstipranks
Blurbs

Analysts Have Conflicting Sentiments on These Healthcare Companies: BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR) and Arcus Biosciences (RCUS)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on BioMarin Pharmaceutical (BMRNResearch Report), United Therapeutics (UTHRResearch Report) and Arcus Biosciences (RCUSResearch Report).

BioMarin Pharmaceutical (BMRN)

In a report released today, Andreas Argyrides from Wedbush reiterated a Hold rating on BioMarin Pharmaceutical, with a price target of $70.00. The company’s shares closed last Wednesday at $88.40.

According to TipRanks.com, Argyrides is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -24.8% and a 20.8% success rate. Argyrides covers the Healthcare sector, focusing on stocks such as Rani Therapeutics Holdings, Global Blood Therapeutics, and Clearside Biomedical.

Currently, the analyst consensus on BioMarin Pharmaceutical is a Strong Buy with an average price target of $110.00.

See Insiders’ Hot Stocks on TipRanks >>

United Therapeutics (UTHR)

Wedbush analyst Liana Moussatos reiterated a Buy rating on United Therapeutics today and set a price target of $263.00. The company’s shares closed last Wednesday at $228.52.

According to TipRanks.com, Moussatos has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -12.9% and a 30.8% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Pacira Pharmaceuticals, and Aquestive Therapeutics.

United Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $256.11, which is a 13.6% upside from current levels. In a report released yesterday, Credit Suisse also maintained a Buy rating on the stock with a $254.00 price target.

Arcus Biosciences (RCUS)

In a report released today, Zhiqiang Shu from Berenberg Bank maintained a Buy rating on Arcus Biosciences, with a price target of $68.00. The company’s shares closed last Wednesday at $26.35.

According to TipRanks.com, Shu has 0 stars on 0-5 stars ranking scale with an average return of -23.9% and a 23.5% success rate. Shu covers the Healthcare sector, focusing on stocks such as Black Diamond Therapeutics, Monte Rosa Therapeutics, and Sensei Biotherapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arcus Biosciences with a $50.83 average price target, representing a 96.0% upside. In a report released yesterday, Mizuho Securities also maintained a Buy rating on the stock with a $51.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BMRN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More